Literature DB >> 19626153

Local Excision vs. Radical Resection in T1-2 Rectal Carcinoma: Results of a Study From the Surveillance, Epidemiology, and End Results (SEER) Registry Data.

L J Hazard1, D C Shrieve, B Sklow, L Pappas, K M Boucher.   

Abstract

BACKGROUND: Local excision (LE) has been used in an attempt to preserve anal function in T1-2 rectal carcinoma. The current study compares LE to radical resection (RR), each with or without radiation therapy (RT).
METHODS: Patients reported to the SEER registry of the National Cancer Institute from 1988 to 2003 who had T1-2N0M0 rectal carcinoma were identified. A retrospective analysis of survival was performed using the Kaplan-Meier method. Comparative risks of mortality were evaluated using multivariate adjusted Cox regression models.
RESULTS: Of 4,320 patients, 13% underwent LE alone, 7% underwent LE plus RT, 70% underwent RR alone, and 10% underwent RR plus RT. On multivariate analysis, patients who underwent LE without RT had inferior overall survival compared to patients who underwent RR (P < .05). Patients who underwent LE with or without RT had inferior cause-specific survival compared to patients who underwent RR (P < .05).
CONCLUSIONS: RR without RT was associated with superior overall survival compared to LE without RT, and RR without RT was associated with superior cause-specific survival compared to LE with or without RT. Randomized trials are necessary to determine if LE with or without RT can offer equivalent survival compared to RR in early stage rectal carcinoma.

Entities:  

Year:  2009        PMID: 19626153      PMCID: PMC2713135     

Source DB:  PubMed          Journal:  Gastrointest Cancer Res        ISSN: 1934-7820


  34 in total

1.  Limitations of early rectal cancer nodal staging may explain failure after local excision.

Authors:  Ron G Landmann; W Douglas Wong; Joseph Hoepfl; Jinru Shia; José G Guillem; Larissa K Temple; Philip B Paty; Martin R Weiser
Journal:  Dis Colon Rectum       Date:  2007-10       Impact factor: 4.585

2.  Long-term results in patients with T2-3 N0 distal rectal cancer undergoing radiotherapy before transanal endoscopic microsurgery.

Authors:  E Lezoche; M Guerrieri; A M Paganini; M Baldarelli; A De Sanctis; G Lezoche
Journal:  Br J Surg       Date:  2005-12       Impact factor: 6.939

3.  Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer.

Authors:  Claus Rödel; Torsten Liersch; Robert Michael Hermann; Dirk Arnold; Thomas Reese; Matthias Hipp; Alois Fürst; Nimrod Schwella; Michael Bieker; Gunter Hellmich; Hermann Ewald; Jörg Haier; Florian Lordick; Michael Flentje; Heiko Sülberg; Werner Hohenberger; Rolf Sauer
Journal:  J Clin Oncol       Date:  2007-01-01       Impact factor: 44.544

4.  Metastatic potential in T1 and T2 colorectal cancer.

Authors:  Wen-Liang Fang; Shih-Ching Chang; Jen-Kou Lin; Haunn-Sheng Wang; Shung-Haur Yang; Jen-Kae Jiang; Wei-Chone Chen; Tzu-Chen Lin
Journal:  Hepatogastroenterology       Date:  2005 Nov-Dec

5.  Patient assessment of bowel function during and after pelvic radiotherapy: results of a prospective phase III North Central Cancer Treatment Group clinical trial.

Authors:  Michael G Haddock; Jeff A Sloan; John W Bollinger; Gamini Soori; Preston D Steen; James A Martenson
Journal:  J Clin Oncol       Date:  2007-04-01       Impact factor: 44.544

6.  Anal sphincter conservation for patients with adenocarcinoma of the distal rectum: long-term results of radiation therapy oncology group protocol 89-02.

Authors:  A H Russell; J Harris; P J Rosenberg; W T Sause; B J Fisher; J P Hoffman; W G Kraybill; R W Byhardt
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-01-15       Impact factor: 7.038

7.  Adverse effects of preoperative radiation therapy for rectal cancer: long-term follow-up of the Swedish Rectal Cancer Trial.

Authors:  Helgi Birgisson; Lars Påhlman; Ulf Gunnarsson; Bengt Glimelius
Journal:  J Clin Oncol       Date:  2005-12-01       Impact factor: 44.544

8.  Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results.

Authors:  Brian G Czito; Johanna C Bendell; Christopher G Willett; Michael A Morse; Gerard C Blobe; Douglas S Tyler; John Thomas; Kirk A Ludwig; Christopher R Mantyh; Jill Ashton; Daohai Yu; Herbert I Hurwitz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-06-01       Impact factor: 7.038

9.  Is the increasing rate of local excision for stage I rectal cancer in the United States justified?: a nationwide cohort study from the National Cancer Database.

Authors:  Y Nancy You; Nancy N Baxter; Andrew Stewart; Heidi Nelson
Journal:  Ann Surg       Date:  2007-05       Impact factor: 12.969

10.  A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer.

Authors:  F Willeke; K Horisberger; U Kraus-Tiefenbacher; F Wenz; A Leitner; A Hochhaus; R Grobholz; A Willer; G Kähler; S Post; R-D Hofheinz
Journal:  Br J Cancer       Date:  2007-02-27       Impact factor: 7.640

View more
  10 in total

1.  Transanal endoscopic microsurgery for rectal cancer. Long-term oncologic results.

Authors:  Jose M Ramirez; Vicente Aguilella; Javier Valencia; Javier Ortego; Jose A Gracia; Pilar Escudero; Ricardo Esco; Mariano Martinez
Journal:  Int J Colorectal Dis       Date:  2011-01-27       Impact factor: 2.571

2.  Functional and clinical results of transanal endoscopic microsurgery combined with endoscopic posterior mesorectum resection for the treatment of patients with t1 rectal cancer.

Authors:  Piotr Walega; Jakub Kenig; Piotr Richter; Wojciech Nowak
Journal:  World J Surg       Date:  2010-07       Impact factor: 3.352

3.  When less is more, when less is less: local excision in early rectal cancer.

Authors:  Joshua E Meyer; David L Sherr
Journal:  Gastrointest Cancer Res       Date:  2009-05

4.  Role of local excision in the management of rectal cancer: what does the future hold?

Authors:  P A Cataldo
Journal:  Tech Coloproctol       Date:  2016-10-20       Impact factor: 3.781

5.  Chemoradiation and Local Excision for T2N0 Rectal Cancer Offers Equivalent Overall Survival Compared to Standard Resection: a National Cancer Database Analysis.

Authors:  Lawrence Lee; Justin Kelly; George J Nassif; Sam B Atallah; Matthew R Albert; Ravi Shridhar; John R T Monson
Journal:  J Gastrointest Surg       Date:  2017-08-17       Impact factor: 3.452

6.  Is limited surgery justified in the treatment of T1 colorectal cancer?

Authors:  Pamela Kogler; Reinhold Kafka-Ritsch; Dietmar Öfner; Michael Sieb; Florian Augustin; Johann Pratschke; Matthias Zitt
Journal:  Surg Endosc       Date:  2012-12-12       Impact factor: 4.584

7.  Primary local excision of stage 1 rectal cancer is not associated with worse oncological outcomes when compared with major resection.

Authors:  Ryan Cohen; Cameron Platell
Journal:  Int J Colorectal Dis       Date:  2020-01-23       Impact factor: 2.571

8.  The outcome of transanal endoscopic microsurgery and adjuvant radiotherapy in patients with high-risk T1 rectal cancer.

Authors:  Wisam Khoury; Mai Dauod; Mohamed Khalefah; Simon D Duek; Nidal Issa
Journal:  J Minim Access Surg       Date:  2022 Apr-Jun       Impact factor: 1.407

9.  Transanal endoscopic microsurgery combined with endoscopic posterior mesorectum resection in the treatment of patients with T1 rectal cancer - 3-year results.

Authors:  Piotr Wałęga; Jakub Kenig; Piotr Richter
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2014-01-30       Impact factor: 1.195

10.  Long-term oncological outcomes of local excision versus radical resection for early colorectal cancer in young patients without preoperative chemoradiotherapy: a population-based propensity matching study.

Authors:  Bin Cao; Li Min; Shengtao Zhu; Haiyun Shi; Shutian Zhang
Journal:  Cancer Med       Date:  2018-05-03       Impact factor: 4.452

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.